MAGL-IN-1 exhibits antiproliferative effects against human breast, colorectal, and ovarian cancer cells; it acts as a potent, selective, reversible, and competitive inhibitor of MAGL (monoacylglycerol lipase) with an IC50 of 80 nM, effectively blocking MAGL activity both in vitro and in vivo.